|
Variable
|
Group
|
n
|
Baseline
|
Post
|
Time
|
Group x Time
|
|---|
|
Triglycerides
|
MIPS
|
10
|
90.6 ± 27.1
|
118.5 ± 41.6
|
0.1124
|
0.571
|
|
mg/dL
|
Placebo
|
7
|
89.3 ± 26.9
|
102.9 ± 47.8
| | |
|
Total Cholesterol
|
MIPS
|
13
|
150.4 ± 31.4
|
145.0 ± 18.6
|
0.9464
|
0.273
|
|
mg/dL
|
Placebo
|
9
|
162.8 ± 47.5
|
167.6 ± 41.5
| | |
|
HDL
|
MIPS
|
13
|
44.5 ± 7.4
|
42.6 ± 8.2
|
0.3284
|
0.978
|
|
mg/dL
|
Placebo
|
11
|
45.0 ± 13.2
|
43.1 ± 6.6
| | |
|
LDL
|
MIPS
|
10
|
89.5 ± 29.0
|
82.7 ± 19.4
|
0.9253
|
0.201
|
|
mg/dL
|
Placebo
|
7
|
103.7 ± 29.7
|
109.5 ± 46.6
| | |
|
Non-HDL
|
MIPS
|
13
|
105.9 ± 30.0
|
101.2 ± 21.1
|
0.9725
|
0.249
|
|
mg/dL
|
Placebo
|
9
|
117.8 ± 47.6
|
122.2 ± 43.5
| | |
|
Glucose
|
MIPS
|
12
|
94.4 ± 4.0
|
97.1 ± 10.1
|
0.2655
|
0.821
|
|
mg/dL
|
Placebo
|
10
|
92.1 ± 10.4
|
94.0 ± 6.8
| | |
|
Cortisol
|
MIPS
|
13
|
123.4 ± 57.2
|
123.4 ± 65.8
|
0.5071
|
0.503
|
|
nmol/L
|
Placebo
|
11
|
116.2 ± 37.1
|
98.4 ± 31.5
| | |
|
Endogenous Nitrite
|
MIPS
|
13
|
5.3 ± 1.6
|
5.2 ± 1.1
|
0.9663
|
0.761
|
|
(μmol/L)
|
Placebo
|
11
|
5.3 ± 1.2
|
5.4 ± 1.4
| | |
|
Total Nitrite
|
MIPS
|
13
|
18.4 ± 18.5
|
17.9 ± 18.0
|
0.7688
|
0.957
|
|
(μmol/L)
|
Placebo
|
11
|
20.6 ± 20.6
|
20.2 ± 20.2
| | |
|
Nitrate
|
MIPS
|
13
|
13.1 ± 6.5
|
12.7 ± 11.0
|
0.7782
|
0.978
|
|
(μmol/L)
|
Placebo
|
11
|
15.3 ± 6.5
|
14.8 ± 9.1
| | |
|
Nitrate/Nitrite
|
MIPS
|
13
|
0.5 ± 0.4
|
0.7 ± 0.7
|
0.3325
|
0.629
|
| |
Placebo
|
11
|
0.4 ± 0.2
|
0.4 ± 0.3
| | |
|
hs-CRP
|
MIPS
|
11
|
1.0 ± 0.87
|
1.1 ± 0.97
|
0.1478
|
0.199
|
|
(mg/L)
|
Placebo
|
8
|
0.78 ± 0.89
|
2.1 ± 2.7
| | |
- Data are mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; Non-HDL, total cholesterol minus HDL; hs-CRP, high-sensitivity C-reactive protein. MIPS, multi-ingredient performance supplement. Placebo, carbohydrate placebo. Sample size between each analyte is slightly different due technical difficulties with certain samples.
